---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-010920"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:49:09.696093+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BridgeBio licenses acoramidis to Bayer for EU rights; up to $310M milestones plus royalties

## Summary
- Eidos grants Bayer exclusive license to develop/commercialize acoramidis (AG10) for ATTR amyloidosis in EU and European Patent Organization.
- BridgeBio eligible for up to $310M in upfront, regulatory, and sales milestone payments through 2026.
- Additional payments subject to achievement of further sales milestones.
- Tiered royalties starting in low-thirties percent on net sales in Licensed Territory.
- Agreement subject to antitrust clearance; termination rights for material breach, insolvency, or Bayer convenience (270 days' notice).

## SEC filing metadata
- accession: 0001140361-24-010920
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036124010920/0001140361-24-010920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036124010920/ef20022786_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-010920
- JSON: https://secwatch.observer/filing/0001140361-24-010920.json
- Plain text: https://secwatch.observer/filing/0001140361-24-010920.txt

## Key facts
- Material Agreements
  BridgeBio Pharma, Inc. entered into Agreement with Bayer Consumer Care AG valued at up to $310 million in upfront, regulatory, and sales milestone payments (effective 2024-03-01).
  - Action: entry
  - Agreement: license
  - Counterparty: Bayer Consumer Care AG
  - Value: up to $310 million in upfront, regulatory, and sales milestone payments
  - Effective: 2024-03-01
  source text: On March 1, 2024, certain subsidiaries of BridgeBio Pharma, Inc. (the “Company”), including Eidos Therapeutics, Inc. (“Eidos”), BridgeBio International GmbH and BridgeBio Europe B.V., entered into an exclusive license agreement (the “Agreement”) with Bayer Consumer Care AG, a wholly-owned subsidiary of Bayer AG (“Bayer”), to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in the European Union and all member states of the European Patent Organization (the “Licensed Territory”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036124010920/0001140361-24-010920-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.